Tumor angiogenesis;Angiogenèse tumorale

Bulletin du Cancer

Volumn 93, Issue SPEC. ISS. APR., 2006, Pages 154-164

  Bikfalvi, Andréas ^a  

^a NONE

Author keywords

Angiogenic switch; Angiopoietin; Angiostatin; Endostatin; Fibroblastic growth factor (FGF); Platelet factor 4; Vasculo endothelial growth factors (VEGF)

Indexed keywords

ANGIOPOIETIN; ANGIOSTATIN; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; HEMOPEXIN; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CARCINOGENESIS; HUMAN; LYMPHANGIOGENESIS; METASTASIS; OXYGEN SUPPLY; TUMOR CELL;

EID: 33745476730     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Algire GH, Chalkely HW, Legallais FY, Park H. Vascular reactions of normal and malignant tumors in vivo: I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945; 6: 73-85.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
3. Hagedorn M, Bikfalvi A. Target molecules for anti-angiogenic therapy: from basic research to clinical trials. Crit Rev Oncol Hematol 2000; 34: 89-110.
4. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and haematopoietic precursor cells blocks tumour angiogenesis and growth. Nat Med 2001; 7: 1194-201.
5. Bikfalvi A, Bicknell R. Recent advances in angiogenesis, antiangiogenesis and vascular targeting. Trends Pharmacol Sci 2002; 23: 576-82.
6. Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med 2002; 8: 483-9.
7. Compagni A, Wilgenbus P, Impagnatiello MA, et al. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 2000; 60: 7163-9.
8. Inoue M, Hager JH, Ferrara N, et al. VEGF-A has a critical, non-redundant role in angiogenic switching and pancreatic β-cell carcinogenesis. Cancer Cell 2002: 193-202.
9. Bergers G, Javaherian K, Lo KM, et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284: 808-12.
10. Rak J, Kerbel RS. Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol 2001; 333: 267-83.
11. Yu JL, Rak JW, Coomber BL, et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002; 295: 1526-8.
12. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-92.
13. Harris AL. Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
14. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
15. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev; 82: 673-700.
16. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001; 22: 201-7.
17. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001; 26: 25-35.
18. Rafii S, Meeus S, Dias S, et al. Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol 2002; 13: 61-7.
19. Miao HQ, Klagsbrun M. Neuropilin is a mediator of angiogenesis. Cancer Metastasis Rev 2000; 19: 29-37.
20. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735.
21. Carmeliet P, Ng YS, Nuyens D, et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 1999; 5: 495-502.
22. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575-83.
23. Holash J, Davis S, Papadopoulos N, et at. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393-8.
24. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2: 1-12; (3005).
25. Goldfarb M. Signaling by fibroblast growth factors: the inside story. Sci STKE 2001; 106: PE37.
26. Matsumoto T, Turesson I, Book M, et al. p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis. J Cell Biol 2002; 156: 149-60.
27. Horowitz A, Tkachenko E, Simons M, et al. Fibroblast growth factor-specific modulation of cellular response by syndecan-4. J Cell Biol 2002; 157: 715-25.
28. Auguste P, Gursel DB, Lemiere S, et al. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res 2001; 61: 1717-22.
29. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
30. Uemura A, Ogawa M, Hirashima M, et al. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest 2002; 110: 1619-28.
31. Rich JN. The role of transforming growth factor- β in primary brain tumors. Front Biosci 2003; 8: E245-E260.
32. Tuxhorn JA, McAlhany SJ, Yag F, et al. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002; 62: 6021-5.
33. Uyttendaele H, Ho J, Rossant J, Kitajewski J. Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium. Proc Natl Acad Sci USA 2001; 98: 5643-8.
34. Mailhos C, Modlich U, Lewis J, et al. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 2001; 69: 135-44.
35. Pola R, Ling LE, Silver M, et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med 2001; 7: 706-11.
36. Adams RH, Klein R. Eph receptors and ephrin ligands essential mediators of vascular development. Trends Cardiovasc Med 2000; 10: 183-8.
37. Brantley DM, Cheng N, Thompson EJ, et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002; 21: 7011-26.
38. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-39.
39. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. Cell Mol Med 2002; 6: 1-12.
40. Hawighorst T, Velasco P, Streit M, et al. Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J 2001; 20: 2631-40.
41. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
42. Fukai N, Eklund L, Marneros AG, et al. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J 2002; 21: 1535-44.
43. Brooks PC, Silletti S, Von Schalscha TL, et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92: 391-400.
44. Bello L, Lucini V, Carrabba G, et al. Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res 2001; 61: 8730-6.
45. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990; 247: 77-9.
46. Perollet C, Han ZC, Savona C, et al. A Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 1998; 91: 3289-96.
47. Hagedorn M, Zilberberg L, Lozano RM, et al. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J 2001; 15: 550-2.
48. Hagedorn M, Zilberberg L, Wilting J, et al. Domain swapping in a COOH-terminal fragment of platelet factor-4 generates potent angiogenesis inhibitors. Cancer Res 2002; 62: 6884-90.
49. Le Couter J, Ferrara N. EG-VEGF and the concept of tissue-specific angiogenic growth factors. Semin Cell Dev Biol 2002; 13: 3-8.
50. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002; 2: 83-90.
51. Peek R, Kammerer RA, Frank S, et al. The angiopoietin-like factor cornea-derived transcript 6 is a putative morphogen for human cornea. J Biol Chem 2002; 277: 686-93.
52. Toft DJ, Rosenberg SB, Bergers G, et al. Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression. Proc Natl Sci USA 2001; 98: 13055-9.
53. Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001; 107: 789-800.
54. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002; 1: 219-27.
55. Oliver G, Detmar M. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev 2002; 16: 773-83.
56. Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002; 62: 2731-5.
57. Burrows FJ, Thorpe PE. Eradication of large solid tumours in mice with an immunotoxin directed against tumour vasculature. Proc Natl Acad Sci USA 1993; 90: 8996-9000.
58. Halin C, Rondini S, Nilsson F, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002; 20: 264-9.
59. Bello L, Carrabba G, Giussani C, et al. A. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001; 61: 7501-6.
60. Bello L, Giussani C, Carrabba G, et al. Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. Clin Cancer Res 2002; 8: 3539-48.